CO5590971A2 - Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina - Google Patents
Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteinaInfo
- Publication number
- CO5590971A2 CO5590971A2 CO05061313A CO05061313A CO5590971A2 CO 5590971 A2 CO5590971 A2 CO 5590971A2 CO 05061313 A CO05061313 A CO 05061313A CO 05061313 A CO05061313 A CO 05061313A CO 5590971 A2 CO5590971 A2 CO 5590971A2
- Authority
- CO
- Colombia
- Prior art keywords
- galactose
- culture
- sialylation
- processes
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1.- La presente invención describe métodos y procesos para la producción de proteínas, particularmente glicoproteínas, por células animales o cultivos celulares de mamífero, ilustrativamente, pero no limitado a, cultivos celulares de lote alimentado. Los métodos comprenden alimentar las células con D-galactosa, preferiblemente con un medio de alimentación que contiene D-galactosa, preferiblemente diariamente, para sostener un nivel de sialilación efectivo de D-galactosa en el cultivo para su duración, incrementando de esta manera la sialilación de las proteínas producidas. Los métodos también pueden comprender al menos dos cambios de temperatura realizados durante el período de cultivo, en el cual la temperatura es menor al final del periodo de cultivo que al momento de iniciar el cultivo celular. El proceso de cultivo celular de la invención involucra dos o más cambios de temperatura sosteniendo una viabilidad celular alta, y puede permitir una fase de producción de proteína extendida. Los métodos también pueden comprender la adición retardada del compuesto polianiónico a un tiempo después de la inoculación. La complementación de los cultivos con D-galactosa, preferiblemente en un medio de alimentación, para sostener la galactosa a niveles efectivos de sialilación en los cultivos hasta el final de la corrida de cultivo invirtiendo una declinación en la sialilación que acompaña la escala de cultivo, y es ventajoso para procesos de cultivo a gran escala.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43605002P | 2002-12-23 | 2002-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5590971A2 true CO5590971A2 (es) | 2005-12-30 |
Family
ID=32682324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05061313A CO5590971A2 (es) | 2002-12-23 | 2005-06-22 | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina |
Country Status (22)
Country | Link |
---|---|
US (2) | US7332303B2 (es) |
EP (1) | EP1576182B2 (es) |
JP (1) | JP4496086B2 (es) |
KR (1) | KR101088223B1 (es) |
CN (1) | CN100402660C (es) |
AT (1) | ATE488600T1 (es) |
AU (1) | AU2003303394B2 (es) |
BR (1) | BR0316882A (es) |
CA (1) | CA2508925C (es) |
CO (1) | CO5590971A2 (es) |
CY (1) | CY1111358T1 (es) |
DE (1) | DE60335024D1 (es) |
DK (1) | DK1576182T4 (es) |
ES (1) | ES2354610T5 (es) |
HK (1) | HK1075474A1 (es) |
IL (1) | IL168873A (es) |
MX (1) | MXPA05006522A (es) |
PL (1) | PL377603A1 (es) |
PT (1) | PT1576182E (es) |
SI (1) | SI1576182T2 (es) |
TW (1) | TWI328614B (es) |
WO (1) | WO2004058944A2 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
DE60225914T2 (de) | 2001-05-23 | 2009-07-23 | Bristol-Myers Squibb Co. | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen |
TWI312368B (en) * | 2002-12-23 | 2009-07-21 | Bristol Myers Squibb Compan | Mammalian cell culture processes for protein production |
CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
WO2004099396A1 (en) * | 2003-05-09 | 2004-11-18 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
WO2005016266A2 (en) | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
US7815765B2 (en) * | 2004-04-01 | 2010-10-19 | Swei Mu Wang | Method for forming laminated synthetic leather |
CA2603970A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
UA97469C2 (uk) * | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
ES2439641T3 (es) | 2005-12-20 | 2014-01-24 | Bristol-Myers Squibb Company | Composiciones y procedimientos de producción de una composición |
CA2634547C (en) * | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
CN101432301B (zh) | 2006-04-05 | 2014-01-08 | 洛克菲勒大学 | 具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法 |
NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
TW201516149A (zh) | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
AU2007317755A1 (en) * | 2006-10-27 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
NZ603059A (en) * | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
MX2010011598A (es) | 2008-04-22 | 2010-12-15 | Univ Rockefeller | Metodos para identificar compuestos anti-inflamatorios. |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
JP5808249B2 (ja) * | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
CN104974251A (zh) | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
RU2577972C2 (ru) | 2010-04-26 | 2016-03-20 | Новартис Аг | Способ получения рекомбинантного полипептида |
EP2702077A2 (en) * | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
CN103717729B (zh) | 2011-07-08 | 2017-11-21 | 动量制药公司 | 细胞培养方法 |
US10059770B2 (en) | 2012-01-30 | 2018-08-28 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of a glycoprotein composition |
WO2013114165A1 (en) * | 2012-01-30 | 2013-08-08 | Dr Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased afucosylation content |
EP2809772A4 (en) * | 2012-01-30 | 2015-06-03 | Reddys Lab Ltd Dr | PROCESS FOR PREPARING GLYCOPROTEIN COMPOSITION |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
CA3051089C (en) | 2012-05-02 | 2022-04-12 | Life Technologies Corporation | High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9926365B2 (en) | 2012-06-29 | 2018-03-27 | Bristol-Myers Squibb Company | Methods for reducing glycoprotein aggregation |
US9664671B2 (en) | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
TWI612135B (zh) * | 2012-08-23 | 2018-01-21 | 日產化學工業股份有限公司 | 動物細胞用培養基之製造方法、動物細胞用培養基、蛋白質的製造方法、及促進培養中的動物細胞的蛋白質產生量的方法 |
US10017805B2 (en) | 2012-08-23 | 2018-07-10 | Nissan Chemical Industries, Ltd. | Enhancing ingredients for protein production from various cells |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014062535A1 (en) | 2012-10-15 | 2014-04-24 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
US20140106405A1 (en) * | 2012-10-15 | 2014-04-17 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
WO2014151878A2 (en) * | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
TWI625390B (zh) * | 2013-03-14 | 2018-06-01 | 安美基公司 | 用於增加重組蛋白質之甘露糖含量之方法 |
WO2014151230A2 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
WO2014170866A2 (en) * | 2013-04-18 | 2014-10-23 | Dr. Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased galactosylation content |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015116820A1 (en) * | 2014-01-30 | 2015-08-06 | Coherus Biosciences, Inc. | Perfusion media |
MX2016013611A (es) | 2014-04-25 | 2017-02-02 | Bristol Myers Squibb Co | Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana. |
MX2016015785A (es) | 2014-06-18 | 2017-04-25 | Medimmune Llc | Metodos y medios de cultivo celular que comprenden n-acetilcisteina. |
WO2016061066A1 (en) * | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
US20160280767A1 (en) | 2015-03-23 | 2016-09-29 | Lonza Ltd. | Methods for controlling protein glycosylation |
DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
CA2992096A1 (en) * | 2015-07-13 | 2017-01-19 | Life Technologies Corporation | System and method for improved transient protein expression in cho cells |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
CN108350416A (zh) * | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
CN116478907A (zh) * | 2016-06-02 | 2023-07-25 | 克洛索治疗有限公司 | 治疗性重组klotho蛋白及其组合物和方法 |
KR20230093531A (ko) | 2016-11-22 | 2023-06-27 | 클로토 테라퓨틱스, 아이엔씨. | 신규한 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법 |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
CN111321188A (zh) * | 2018-12-17 | 2020-06-23 | 嘉和生物药业有限公司 | 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用 |
TW202128744A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗vegf蛋白組合物及其製備方法 |
CN113025648B (zh) * | 2019-12-09 | 2023-06-02 | 广东菲鹏制药股份有限公司 | Expi293细胞瞬时表达目标蛋白的方法及其应用 |
CN111676184B (zh) * | 2020-05-15 | 2021-01-29 | 上海多宁生物科技有限公司 | 一种由补料培养基共混的基础培养基及其制备方法和应用 |
EP4196597A2 (en) * | 2020-08-14 | 2023-06-21 | Bristol-Myers Squibb Company | Manufacturing process for protein |
EP4284914A1 (en) * | 2021-02-01 | 2023-12-06 | Dr. Reddy's Laboratories Limited | Cell culture methods |
WO2022168774A1 (ja) | 2021-02-08 | 2022-08-11 | 株式会社島津製作所 | 推定装置、学習装置、最適化装置、推定方法、学習方法、および最適化方法 |
WO2024129594A1 (en) * | 2022-12-12 | 2024-06-20 | Genentech, Inc. | Optimizing polypeptide sialic acid content |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4357422A (en) | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
FR2543158B1 (fr) * | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu |
US4994387A (en) | 1983-11-10 | 1991-02-19 | The Wistar Institute | Process and medium for cloning and long-term serial cultivation of human endothelial cells |
US5132223A (en) | 1983-11-10 | 1992-07-21 | Thomas Jefferson University | Process and medium for cloning and long-term serial cultivation of adult human endothelial cells |
US5112749A (en) * | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
DE3801236A1 (de) * | 1988-01-18 | 1989-07-27 | Boehringer Mannheim Gmbh | Pentosansulfat-medium |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
IL92382A (en) | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US5521288A (en) | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
GB9022545D0 (en) † | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
TW318142B (es) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
EP0637963B1 (en) | 1992-04-07 | 2004-08-04 | The Regents of the University of Michigan | Cd28 pathway immunoregulation |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US5348877A (en) | 1993-03-12 | 1994-09-20 | Boyce Thompson Institute For Plant Research, Inc. | Method of adapting anchorage-dependent cell lines to suspension conditions |
WO1994028912A1 (en) | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Cd28 pathway immunosuppression |
SE9303601D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Improved cell cultivation method and medium |
MX9605088A (es) * | 1994-04-28 | 1997-08-30 | Boehringer Ingelheim Pharma | Metodos para proliferar y diferenciar celulas b y sus usos. |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
WO1996030506A1 (en) | 1995-03-24 | 1996-10-03 | Takeda Chemical Industries, Ltd. | Antibody to human betacellulin and use thereof |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JPH11510692A (ja) * | 1995-07-28 | 1999-09-21 | ベス イスラエル ディーコネス メディカル センター,インク. | 突然変異誘発を検査するための方法及び検査器具 |
JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US5728580A (en) * | 1996-02-20 | 1998-03-17 | Cornell Research Foundation, Inc. | Methods and culture media for inducing single cell suspension in insect cell lines |
US6043092A (en) * | 1996-03-18 | 2000-03-28 | University Of Pittsburgh | Cell culture media for mammalian cells |
EP0892643B2 (en) | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US5856159A (en) * | 1996-03-27 | 1999-01-05 | Cytel Corporation | Production of galactosyltransferase |
US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
US20030219863A1 (en) | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
EP1036179B2 (de) † | 1997-12-03 | 2014-01-01 | Roche Diagnostics GmbH | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
DE69929198T2 (de) | 1998-05-29 | 2006-08-10 | Genentech, Inc., South San Francisco | Zellkulturverfahren für die produktion von glycoproteinen |
DE19852729A1 (de) * | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
MXPA01004982A (es) * | 1998-11-18 | 2004-09-27 | Neose Technologies Inc | Manufactura de bajo costo de oligosacaridos. |
TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
WO2000065070A2 (en) | 1999-04-26 | 2000-11-02 | Genentech, Inc. | Cell culture process for glycoproteins |
WO2001059075A1 (en) | 2000-02-08 | 2001-08-16 | Genentech, Inc. | Improved sialylation of glycoproteins |
DE60120356T2 (de) | 2000-02-08 | 2007-06-14 | Genentech, Inc., South San Francisco | Verbesserte galactosylierung von rekombinanten proteinen |
KR100889887B1 (ko) | 2000-05-26 | 2009-03-24 | 브리스톨-마이어스스퀴브컴파니 | 가용성 ctla4 돌연변이 분자 및 그의 용도 |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CA2411962A1 (en) | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
TR201807700T4 (tr) | 2000-07-03 | 2018-06-21 | Squibb Bristol Myers Co | Çözünür CTLA4 mutant moleküllerinin kullanımları. |
US20020099183A1 (en) * | 2000-08-23 | 2002-07-25 | Pluschkell Stefanie Beate | Process for the preparation of neutrophil inhibitory factor |
HUP0303930A3 (en) | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DE60225914T2 (de) | 2001-05-23 | 2009-07-23 | Bristol-Myers Squibb Co. | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen |
CA2492267C (en) † | 2002-07-15 | 2013-09-10 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
US6924124B1 (en) * | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
TWI312368B (en) | 2002-12-23 | 2009-07-21 | Bristol Myers Squibb Compan | Mammalian cell culture processes for protein production |
WO2005016266A2 (en) | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
US20070161047A1 (en) * | 2006-01-09 | 2007-07-12 | Xiaotian Zhong | Methods of labeling transiently expressed proteins in large-scale eukaryotic cell cultures |
-
2003
- 2003-12-18 CN CNB2003801099353A patent/CN100402660C/zh not_active Expired - Lifetime
- 2003-12-18 PL PL377603A patent/PL377603A1/pl not_active Application Discontinuation
- 2003-12-18 JP JP2004563950A patent/JP4496086B2/ja not_active Expired - Lifetime
- 2003-12-18 CA CA2508925A patent/CA2508925C/en not_active Expired - Lifetime
- 2003-12-18 MX MXPA05006522A patent/MXPA05006522A/es active IP Right Grant
- 2003-12-18 AU AU2003303394A patent/AU2003303394B2/en not_active Expired
- 2003-12-18 US US10/740,645 patent/US7332303B2/en not_active Expired - Lifetime
- 2003-12-18 ES ES03808535T patent/ES2354610T5/es not_active Expired - Lifetime
- 2003-12-18 AT AT03808535T patent/ATE488600T1/de active
- 2003-12-18 WO PCT/US2003/040939 patent/WO2004058944A2/en active Application Filing
- 2003-12-18 DE DE60335024T patent/DE60335024D1/de not_active Expired - Lifetime
- 2003-12-18 TW TW092136006A patent/TWI328614B/zh not_active IP Right Cessation
- 2003-12-18 KR KR1020057011764A patent/KR101088223B1/ko active IP Right Grant
- 2003-12-18 PT PT03808535T patent/PT1576182E/pt unknown
- 2003-12-18 SI SI200331927T patent/SI1576182T2/sl unknown
- 2003-12-18 EP EP03808535.3A patent/EP1576182B2/en not_active Expired - Lifetime
- 2003-12-18 BR BR0316882-4A patent/BR0316882A/pt not_active IP Right Cessation
- 2003-12-18 DK DK03808535.3T patent/DK1576182T4/da active
-
2005
- 2005-05-30 IL IL168873A patent/IL168873A/en active IP Right Grant
- 2005-06-22 CO CO05061313A patent/CO5590971A2/es not_active Application Discontinuation
- 2005-11-02 HK HK05109747.2A patent/HK1075474A1/xx not_active IP Right Cessation
-
2007
- 2007-10-22 US US11/975,799 patent/US20080070280A1/en not_active Abandoned
-
2011
- 2011-02-14 CY CY20111100184T patent/CY1111358T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5590971A2 (es) | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina | |
TW200512297A (en) | Mammalian cell culture processes for protein production | |
Pham et al. | Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis | |
Ljunggren et al. | Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures | |
JP6347949B2 (ja) | 改良型細胞培養培地 | |
US6406909B1 (en) | Serum-free medium for culturing animal cells | |
EA200501774A1 (ru) | Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции | |
SI1543106T1 (sl) | Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice | |
EA201490631A1 (ru) | Способы культивирования клеток млекопитающих для получения белка | |
WO2005028626A3 (en) | Cell culture media | |
UA92157C2 (ru) | Способ продуцирования гормона роста | |
WO2002101019A3 (en) | Methods of culturing animal cells and polypeptide production in animal cells | |
EP3495491A1 (en) | Method for producing recombinant protein | |
EP4349959A1 (en) | Composition for culturing algae and algae culturing method | |
BRPI0517942B8 (pt) | processo para a produção do hormônio de crescimento humano recombinante (rhgh) e usos de um meio de cultura de células isento de soro | |
DE69923595D1 (de) | Herstellung von proteinen | |
TNSN01128A1 (en) | Process for the preparation of a neutrophil inhibitory factor | |
Cruz et al. | Correlation between BHK Cell Specific Productivity and Metabolism | |
UA81564C2 (ru) | Способ дифференциации стромальных столбовых клеток человека в культуральной среде in vitro | |
CN104830750A (zh) | 一种驴皮成纤维细胞体外快速培养的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |